Keith Spedding
Advisers at law firm, Shakespeare Martineau, have assisted Bermele plc with a £1 million capital-raising move. It has become a cash shell on the Standard List and begun trading on the London Stock Exchange.
Bermele plc is a special purpose acquisition vehicle, formed to acquire commercial technologies in the life sciences, pharmaceutical and biotechnology sectors.
Recognising the rapid pace of innovation in these scientific fields has highlighted this area as one ripe for investment. It is hoped that the move will allow the business to invest in innovative companies focusing on medical and technological advancements in the areas of diabetes, cancer, mental health and personalised medicines.
Bermele was advised on the finance raising process by Shakespeare Martineau’s corporate team, who provided guidance on all legal areas of the transaction, including technical contractual elements and corporate governance. Novum Securities acted as broker.
Keith Spedding, Corporate Partner at law firm, Shakespeare Martineau, who acted as lead adviser, said: “Bermele has shown the faith it has in the UK and international life sciences and biotechnology sectors. As one of the fastest-developing fields of innovation, these areas are an extremely attractive proposition for forward-thinking investors, such as Bermele plc.
“Against the uncertainty which pervades all areas of UK business, this finance raising operation is testament to the success of the both the UK and international markets. For smaller companies on the hunt for funding, seeing investors such as Bermele position itself as being open for business, should be a real vote of confidence.”
Toby Hayward, Chairman of Bermele plc, said: “We have recognised that the pharmaceutical and biotechnology sectors are driven by a need for more effective new products and technologies to help in the diagnosis, treatment and prevention of a multitude of illnesses and conditions. It’s a fast-paced section of the market, with ground-breaking new developments being made on almost a daily basis.
“Undergoing this transaction will allow us to engage with, and support, a number of incredibly innovative businesses, aiding them on their growth trajectories.”
